Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
GE Vernova is significantly deepening its commitment to the Indian market through a series of initiatives.

GE Vernova is significantly deepening its commitment to the Indian market through a series of initiatives.

老虎证券老虎证券2026/06/04 13:21
Show original
The company has launched a brand-new 3.8 MW flagship wind turbine, aiming to meet the growing local market demand for efficient and reliable energy solutions. Meanwhile, GE Vernova has secured an important wind turbine order from Powerica, further solidifying its market position in India’s renewable energy sector. The company has also successfully obtained India’s ALMM (Approved List of Models and Manufacturers) certification, a key milestone demonstrating that its products meet domestic standards and requirements in India.To strengthen local production capacity, GE Vernova is expanding its manufacturing base in Pune. This investment will boost indigenous manufacturing levels and better serve India and neighboring markets, highlighting the company’s long-term commitment to India’s energy transition.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage